Gemini Therapeutics (GMTX) Income Statement & Balance Sheet → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free GMTX Stock Alerts $30.77 +1.43 (+4.87%) (As of 05/9/2024 ET) Add Compare Share Share FinancialsStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial MediaStock AnalysisChartCompetitorsFinancialsHeadlinesInsider TradesSEC FilingsSocial Media Gemini Therapeutics Income Statement, Balance Sheet and Cash Flow Statement→ Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (Ad) Related Companies: Pacira BioSciences Financial Statements Ligand Pharmaceuticals Financial Statements Ironwood Pharmaceuticals Financial Statements Collegium Pharmaceutical Financial Statements Verona Pharma Financial Statements Spyre Therapeutics Financial Statements Belite Bio Financial Statements Mirum Pharmaceuticals Financial Statements Xencor Financial Statements Kiniksa Pharmaceuticals Financial Statements Receive GMTX Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Gemini Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:GMTX) was last updated on 5/10/2024 by MarketBeat.com Staff From Our Partners[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaCharles Payne Demystifies OptionsUnstoppable ProsperityForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingYou need to know these two things about AI stocks ASAP…InvestorPlaceShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport Society Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gemini Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
